bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.
Nordic Countries
Need information ?
Contact us
News
bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test
24 March, 2020bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical...
bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance
14 January, 2020
bioMérieux – 2019 Financial Results
14 January, 2020
bioMérieux – Third-Quarter 2019 Business Review
22 October, 2019
bioMérieux – First-Half 2019 Results
04 September, 2019
bioMérieux – First-Half 2018 Results
05 September, 2018